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A B S T R A C T
Purpose: PCDH19 mutations cause epilepsy and mental retardation limited to females (EFMR) or
Dravet-like syndromes. Especially in the ﬁrst years of life, epilepsy is known to be highly
pharmacoresistant. The aim of our study was to evaluate the effectiveness of antiepileptic therapy in
patients with PCDH19 mutations.
Methods: We report a retrospective multicenter study of antiepileptic therapy in 58 female patients with
PCDH19 mutations and epilepsy aged 2–27 years (mean age 10.6 years).
Results: The most effective drugs after 3 months were clobazam and bromide, with a responder rate
of 68% and 67%, respectively, where response was deﬁned as seizure reduction of at least 50%. Deﬁning
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J. Lotte et al. / Seizure 35 (2016) 106–110 107long-term response as the proportion of responders after 12 months of treatment with a given drug in
relation to the number of patients treated for at least 3 months, the most effective drugs after 12 months
were again bromide and clobazam, with a long-term response of 50% and 43%, respectively. Seventy-four
percent of the patients became seizure-free for at least 3 months, 47% for at least one year.
Signiﬁcance: The most effective drugs in patients with PCDH19 mutations were bromide and clobazam.
Although epilepsy in PCDH19 mutations is often pharmacoresistant, three quarters of the patients
became seizure-free for at least for 3 months and half of them for at least one year. However, assessing
the effectiveness of the drugs is difﬁcult because a possible age-dependent spontaneous seizure
remission must be considered.
 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Treatment
Long-term
effectivenessTable 1
Clinical features of the included 58 patients.
Age 10.6 years (2–27 years)
Age at seizure onset 11.2 months (3–78 months)
Different seizure types 2.5 (1–6)
Generalized tonic clonic seizures 81%
At least 2 different seizures types 74%
Clusters of seizures 93%
at least one status epilepticus 45%
Provocation factors for seizures
Fever 76%
Afebrile infections 41%
Vaccinations 14%
Emotional stress 12%
Hot bathing 2%
Motor activity None
Photostimulation None1. Introduction
Mutations in the PCDH19 gene were originally identiﬁed by
Dibbens et al. in patients with epilepsy and mental retardation
limited to females (or Epilepsy, Female-restricted, with Mental
Retardation, EFMR; OMIM# 300088) [8]. The clinical features of
EFMR are highly variable. Early onset of seizures (6–36 months)
and precipitation during fever are characteristic [5,7,11,13]. Sei-
zures are focal or generalized, including tonic-clonic, myoclonic,
atonic or absence seizures [10,12]. They often occur in clusters or
as prolonged ictal episode, occasionally leading to status epilepti-
cus. In the course of the disease, seizure cessation is common
[6]. Early development is usually normal and often accompanied
by regression at the time of seizure onset or later, with a varying
degree of intellectual disability [10,12]. Behavioral problems are
frequently part of the clinical picture and can manifest as autistic,
obsessive or aggressive features [7,17].
The clinical spectrum associated with PCDH19 mutations can
overlap with Dravet syndrome, which is typically associated with
SCN1A mutations [1,6]. In both syndromes, psychomotor develop-
ment is generally normal before the onset of seizures, secondary
progressive appearance of mental and motor delay and language
regression is observed. In both syndromes, seizures are usually
triggered by fever, and the association with generalized tonic-
clonic and focal seizures is rather typical [2,7].
Treatment of EFMR is difﬁcult. Especially during the ﬁrst years
of life, seizures appear to be highly resistant to antiepileptic drugs,
while their frequency and their pharmacoresistance tend to
decrease during the course of the disease [7,13]. Currently, there
is limited data on treatment of these patients [10], especially, there
is hardly any data on the results of treatment with a particular drug
for more than 6 months, and still there is no clear consensus on
how to treat these patients.
Therefore, the aim of our study was to evaluate the effective-
ness of antiepileptic therapy in patients with PCDH19 mutations
including the data after one year of treatment.
2. Methods
We recruited patients with proven PCDH19 mutations from
25 centers in 12 countries for this retrospective descriptive
multicenter study by sending questionnaires to collaborating
centers, where patients have been cared for regularly and received
an individualized treatment. The clinical information was collected
retrospectively and anonymized, using a questionnaire, which was
ﬁlled out by the treating physicians, based on parents reports.
Ethical approval was obtained from the Bavarian Ethic Commis-
sion.
In the questionnaire, both previous and current antiepileptic
treatments were recorded and the effectiveness of the used
antiepileptic drugs was assessed 3 and 12 months after the
initiation of the respective medication. The inﬂuence on seizureactivity was evaluated as response, non-response or aggravation,
with response being deﬁned as a seizure reduction of at least 50%
after 3 or 12 months.
Response was further subdivided in seizure reduction of 50%,
75%, and 100%, with seizure reduction being deﬁned as per cent
decrease in seizure frequency. The drugs were evaluated only if
they had been taken for at least 3 months in sufﬁciently high doses.
Only drugs used in a minimum of ﬁve patients were included in the
comparison of the effectiveness of the different drugs.
Furthermore, onset of epilepsy, types and duration of seizures,
and provocation factors were recorded, as well as cognitive and
motor development, behavioral disturbances and EEG and MRI
ﬁndings, if available. Regarding duration of seizures we asked for
clusters of seizure and status epilepticus, deﬁned as a seizure
lasting more than 20 min. The old deﬁnition [3] was chosen
because of the retrospective design of the study.
3. Results
We included 58 female patients with PCDH19 mutations, the
clinical features are shown in Table 1. At least initially, 52% of the
patients showed a normal interictal EEG, and in 34% the EEG
remained normal during the follow-up. In patients who underwent
MRI of the brain (n = 48), normal ﬁndings were seen in 81%, a focal
cortical dysplasia (FCD) was diagnosed in 4% and suspected in 10%.
The remaining patients had abnormal MRI ﬁndings independently
of any FCD (1 hippocampal sclerosis, 1 arachnoid cyst).
Most patients were cognitively impaired, had motor disabilities
or behavioral disturbances (see Table 2). The majority of the
children initially showed no abnormalities in development (86%),
and the onset of developmental delay most often coincided with
the seizure onset (82%; data not available for 15 patients). Five girls
had a normal motor, cognitive, and behavioral development
throughout the course of the disease (age at end of observation was
4 to 11 years).
Table 2
Motor, cognitive and behavioral development of patients with reported dis-
turbances (multiple entries possible).
Number of
patients (%)
Motor development Normal motoric
development
33 (57%)
Hypotonia 8 (14%)
Ataxia 18 (31%)
Cognitive development Normal cognitive
development
10 (17%)
Learning disability
(IQ 70–85)
18 (31%)
Mental disability
(IQ <70)
30 (52%)
Behavior Normal behavior 19 (33%)
Hyperactive 12 (21%)
Aggressive 18 (31%)
Aggressive traits 6 (10%)
Autistic 22 (38%)
Autistic traits 5 (9%)
Obsessive 1 (2%)
J. Lotte et al. / Seizure 35 (2016) 106–110108Antiepileptic drugs administered for at least 3 months were
bromide (BR), carbamazepine (CBZ), clobazam (CLB), clonazepam
(CZP), ethosuximide (ESM), gabapentin (GBP), lacosamide (LCM),
levetiracetam (LEV), lamotrigine (LTG), lorazepam (LZP), nitraze-
pam (NZP), oxcarbazepine (OXC), phenobarbital (PB), perampanel
(PER), pregabalin (PGB), phenytoin (PHT), ruﬁnamide (RFN),
sulthiame (STM), stiripentol (STP), topiramate (TPM), vigabatrin
(VGB), valproate (VPA) and zonisamide (ZNS). On average, the
patients received 5.5 different antiepileptic drugs (range 1–12),
most patients (98%; data not available for 14 patients) received at
least temporarily a combination of two or more drugs. In addition,
some patients received steroids, a ketogenic diet (KD) or a vagus
nerve stimulation (VNS). The frequency and effectiveness of
antiepileptic drugs administered for at least 3 months are
summarized in Table 3 and Fig. 1. The frequency and effectiveness
of antiepileptic drugs administered for at least 12 months areTable 3
Effectiveness of AED after 3 months of use. Total number of patients treated with each 
non-response (seizure reduction <50%) or aggravation. Response was further different
Total Response 50–74% 75
BR 6 4 (67%) 1 (17%) 1 
CBZ 26 7 (27%) 2 (8%) 1 
CLB 28 19 (68%) 4 (14%) 3 
CZP 9 4 (44%) 2 (22%) 0 
ESM 2 0 0 0 
GBP 2 0 0 0 
LCM 4 3 (3/4) 0 1 
LEV 38 13 (34%) 5 (13%) 3 
LTG 24 7 (29%) 3 (13%) 1 
LZP 1 1 (1/1) 1 (1/1) 0 
NZP 2 0 0 0 
OXC 21 4 (19%) 2 (10%) 0 
PB 28 12 (43%) 2 (7%) 4 
PER 2 1 (1/2) 0 0 
PGB 1 0 0 0 
PHT 14 1 (7%) 1 (7%) 0 
RFN 6 1 (17%) 1 (17%) 0 
STM 9 1 (11%) 1 (11%) 0 
STP 5 2 (40%) 0 1 
TPM 29 11 (38%) 2 (7%) 1 
VGB 5 1 (20%) 0 0 
VPA 50 22 (44%) 5 (10%) 3 
ZNS 3 1 (1/3) 0 1 
Steroids 3 1 (1/3) 0 0 
KD 4 2 (2/4) 0 1 
VNS 1 1 (1/1) 0 1 summarized in Table 4 and Fig. 2. Long-term response was deﬁned
as the proportion of responders after 12 months in relation to the
number of patients treated for at least 3 months.
Forty-three patients (74%) became seizure-free for at least
3 months. Twenty-six patients (45%) achieved long-term seizure
freedom, 24 of them (41%) for more than one year, 22 of the latter
continued to receive drugs, 13 of them as polytherapy. Two
patients (3%) became seizure-free for more than 10 years, both of
them still receiving polytherapy. Remission occurred at the age of
8 months to 17.3 years (mean: 7.3 years), with 46% of the patients
being younger than 5 years. In patients who became seizure-free in
the long term, the average duration of active seizures was
10.7 years, with a range from 1 month to 11.8 years.
4. Discussion
In this retrospective study, we investigated the effectiveness of
antiepileptic drugs used in patients with PCDH19 mutations and
their clinical course. The clinical evolution of most of our patients
corresponded well with the one reported previously [7,9,14]. Sei-
zure onset occurred mostly in the typical range of 6-36 months.
Notably, there was a relatively large proportion (17%) of girls with
an earlier onset down to 3 months, and one girl with a relatively
late seizure onset at 78 months. In accordance with reports from
other groups, we found many patients with cognitive impairment
and behavioral disturbances [7,9,10]. But at least ﬁve girls (9%)
showed an unremarkable development with respect to motor
function, cognition and behavior. Obviously, the clinical spectrum
of PCDH19 mutations is wider than usually described. Therefore,
PCDH19 mutations are presumably still underdiagnosed as
possible cause of epilepsy. They should also be considered in girls
with an onset of epilepsy signiﬁcantly beyond the typical range
and with an otherwise unremarkable development.
Many of our patients showed features comparable to those of
Dravet syndrome, even though they do not necessarily present
with all the criteria for the clinical diagnosis. Like in children with
SCN1A mutations, seizures were partly triggered by emotional
stress, vaccinations or bathing, although the main provocationantiepileptic drug and number of patients in whom these drugs showed response,
iated into a seizure reduction by 50%, 75% and 100% (seizure free).
–99% 100% Non-response Aggravation
(17%) 2 (33%) 2 (33%) 0
(4%) 4 (15%) 16 (62%) 3 (12%)
(11%) 12 (43%) 9 (32%) 0
2 (22%) 5 (56%) 0
0 2 (2/2) 0
0 2 (2/2) 0
(1/4) 2 (2/4) 0 1 (1/4)
(8%) 5 (13%) 25 (66%) 0
(4%) 3 (13%) 16 (67%) 1 (4%)
0 0 0
0 2 (2/2) 0
2 (10%) 15 (71%) 2 (10%)
(14%) 6 (21%) 16 (57%) 0
1 (1/2) 1 (1/2) 0
0 1 (1/1) 0
0 12 (86%) 1 (7%)
0 4 (67%) 1 (17%)
0 8 (89%) 0
(20%) 1 (20%) 3 (60%) 0
(3%) 8 (28%) 18 (62%) 0
1 (20%) 4 (80%) 0
(6%) 14 (28%) 28 (56%) 0
(1/3) 0 2 (2/3) 0
1 (1/3) 2 (2/3) 0
(1/4) 1 (1/4) 2 (2/4) 0
(1/1) 0 0 0
Fig. 1. Effectiveness of antiepileptic drugs after 3 months of use, differentiated in aggravation, non-response (seizure reduction <50%) and response (seizure reduction 50%).
Response was further differentiated in seizure reduction of 50%, 75% and 100% (seizure free). Only drugs applied in at least 5 patients are shown (KD: n = 4).
Table 4
Effectiveness of AED after 12 months of use. Total number of patients treated with each antiepileptic drug and number of patients in whom these drugs showed response
(seizure reduction 50%) or non-response (seizure reduction <50%). No cases with aggravation were observed. Response was further differentiated into a seizure reduction
by 50%, 75% and 100% (seizure free). Long-term response was deﬁned as the proportion of responders after 12 months in relation to the number of patients treated for at
least 3 months.
Total Response 50–74% 75–99% 100% Non-response Long-term response
BR 4 3 (3/4) 2 (2/4) 0 1 (1/4) 1 (1/4) 50% (3/6)
CBZ 5 3 (60%) 2 (40%) 0 1 (20%) 2 (40%) 12% (3/26)
CLB 15 12 (80%) 3 (20%) 5 (33%) 4 (27%) 3 (20%) 43% (12/28)
CZP 2 2 (2/2) 1 (1/1) 0 1 (1/1) 0 22% (2/9)
ESM 0 0 0 0 0 0 0 (0/2)
GBP 0 0 0 0 0 0 0 (0/2)
LCM 1 1 (1/1) 0 0 1 (1/1) 0 1 (1/4)
LEV 14 8 (57%) 2 (14%) 3 (21%) 3 (21%) 6 (43%) 21% (8/38)
LTG 7 3 (43%) 0 2 (29%) 1 (14%) 4 (57%) 13% (3/24)
LZP 1 1 (1/1) 1 (1/1) 0 0 0 1/1
NZP 1 0 0 0 0 1 (1/1) 0 (0/2)
OXC 4 1 (1/4) 1 (1/4) 0 0 3 (3/4) 5% (1/21)
PB 13 6 (46%) 2 (15%) 1 (8%) 3 (23%) 7 (54%) 21% (6/28)
PER 1 1 (1/1) 0 0 1 (1/1) 0 1/2
PGB 0 0 0 0 0 0 0 (0/1)
PHT 2 1 (1/2) 1 (1/2) 0 0 1 (1/2) 7% (1/14)
RFN 1 0 0 0 0 1 (1/1) 0 (0/6)
STM 2 0 0 0 0 2 (2/2) 0 (0/9)
STP 2 1 (1/2) 0 1 (1/2) 0 1 (1/2) 20% (1/5)
TPM 12 8 (67%) 2 (17%) 2 (17%) 4 (33%) 4 (33%) 28% (8/29)
VGB 2 0 0 0 0 2 (2/2) 0 (0/5)
VPA 28 17 (61%) 3 (11%) 4 (14%) 10 (36%) 11 (39%) 34% (17/50)
ZNS 1 1 (1/1) 1 (1/1) 0 0 0 1/3
Steroids 0 0 0 0 0 0 0 (0/3)
KD 1 1 (1/1) 1 (1/1) 0 0 0 1/4
VNS 1 1 (1/1) 0 1 (1/1) 0 0 1/1
Fig. 2. Effectiveness of antiepileptic drugs after 12 months of use, differentiated in non-response (seizure reduction <50%) and response (seizure reduction 50%). Response
was further differentiated in seizure reduction of 50%, 75% and 100% (seizure free). Long-term response was deﬁned as the proportion of responders after 12 months in
relation to the number of patients treated for at least 3 months. Only drugs applied for 3 months in at least 5 patients are shown (KD: n = 1).
J. Lotte et al. / Seizure 35 (2016) 106–110 109factors were fever and infections. Differences mainly concern the
cognitive development, the seizure provocation and the behavior,
as patients with PCDH19 mutations show less cognitive im-
pairment and fewer provocation factors for seizure initiation, but
present more often with behavioral problems. A characteristic
feature is the occurrence of seizure clusters with relatively long
seizure-free intervals. Accordingly, Dravet syndrome was clinically
diagnosed in one-third of our patients. PCDH19 mutations musttherefore be taken into account for patients with Dravet
symptoms.
In our patients, the most effective drugs after 3 months turned
out to be CLB and BR, the following drugs were signiﬁcant less
effective. Aggravations were rarely observed in our patients. They
were only seen in connection with sodium channel blockers,
although CBZ and LTG showed a relatively good effectiveness.
Compared to the 3 months treatment baseline, the most effective
J. Lotte et al. / Seizure 35 (2016) 106–110110drug after 12 months of treatment was BR, followed by CLB and
VPA. Remarkably, the typical loss of effectiveness of CLB after
several months did not occur in our patients, although sometimes a
decrease in effectiveness was observed [15].
A precise assessment of the effectiveness of antiepileptic drugs
in patients with PCDH19 mutations is difﬁcult. On the one hand,
our study is retrospective, based on parental reports, consequently
involving unavoidable uncertainty. Most patients received at least
temporarily a combination of several drugs, which makes it
difﬁcult to differentiate between the effects of the separate drugs.
The number of patients is limited, more than half of the drugs have
been used in less than 10 patients. On the other hand, seizures in
patients with PCDH19 mutations usually occur in clusters, often
triggered by febrile infections, with seizure-free intervals of
several months, and it is difﬁcult to distinguish the effect of the
drugs from the natural course. An age-dependent and spontaneous
seizure remission must also be considered. After a period of intense
seizure activity at the beginning, there is a frequent reduction in
seizure frequency in most patients [7]. Such an evolution was
particularly impressive in one of our patients with initially up to
40 seizures per day and a spontaneous progressive seizure
decrease up to seizure freedom, so that the drugs could be
completely tapered off without recurrence of seizures at 2 years of
follow-up.
Notably, although epilepsy in PCDH19 mutations is known to be
pharmacoresistant, around three-quarters of our patients were
seizure-free for at least 3 months. Nearly half of them became
seizure-free for more than one year, and two even for over 10 years.
Almost all of them were still on medication, although it was not
clear whether the drugs were required because withdrawal was
not attempted. Due to the initial seizure history, it is understand-
able that families may not want to take the risk of a renewed
deterioration by tapering off the drugs.
There are hardly any reports on medication for epilepsies
associated with PCDH19 mutations. Higurashi et al. [10] reported a
good seizure control especially with PHT, BR and CLB. The
difference in effectiveness of PHT in this study compared to ours
is remarkable, possibly due to the small number of cases in both
studies. It is also noteworthy that in our patients aggravations
occurred only in connection with sodium channel blockers,
whereas Higurashi et al. reported also aggravations in connection
with TPM and VPA [9]. Therapeutic consensus as described for
patients with SCN1A mutations are not yet in sight. On balance,
GABAergic drugs such as BR, CLB and VPA seem promising,
analogous to their therapeutic response in Dravet syndrome
[4,16]. Higurashi et al. reported that the proﬁle of drugs showing
higher efﬁcacy in patients with PCDH19 mutations was similar to
that observed in Dravet syndrome, with the exception of phenytoin
[10]. In a single case report, STP showed a good effect in
combination with CLB and VPA, a well-established therapy in
Dravet syndrome [18]. So maybe therapy concepts used for the
Dravet syndrome with SCN1A mutations could also be successfully
applied in patients with PCDH19 mutations. However, sodium
channel blockers caused signiﬁcantly less aggravations here, but
were often effective.
Remarkably, there was a relatively high proportion of abnormal
MRI ﬁndings, with focal cortical dysplasia being diagnosed or
suspected in several patients. While mechanisms of epileptogen-
esis in PCDH19 mutations are still unclear, the role of proto-
cadherin-19 during brain development suggests that PCDH19
mutations lead to structural malformations [13]. This would ﬁt
well with the observed effectiveness of sodium channel blockers,with few aggravations, but not with the typical course character-
ized by spontaneous seizure reduction.
Further studies are needed to gain a better understanding of the
mechanism of epileptogenesis in PCDH19 mutations and to
develop effective therapeutic strategies. Randomized controlled
studies are desirable, but they are hardly feasible due to the low
patient numbers. We have therefore chosen the retrospective
approach in order to achieve ﬁrst results. Retrospective studies like
ours may help to get an outline of effectiveness of drugs in EFMR
and to develop controlled studies, knowing that the assessment of
drug efﬁcacy will always remain biased by the favorable
spontaneous course. Like with any other patient with epileptic
seizures, to taper the medication after a prolonged seizure-free
period seems safe in these patients and should always be taken
into account.
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